Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-25-005254
Filing Date
2025-04-23
Accepted
2025-04-23 16:01:18
Documents
20
Period of Report
2025-06-03

Document Format Files

Seq Description Document Type Size
1 DEF 14A vygr-20250603xdef14a.htm   iXBRL DEF 14A 1419255
2 GRAPHIC vygr-20250603xdef14a_a008.jpg GRAPHIC 67784
3 GRAPHIC vygr-20250603xdef14a_a009.jpg GRAPHIC 67942
4 GRAPHIC vygr-20250603xdef14a_bg001.jpg GRAPHIC 133461
5 GRAPHIC vygr-20250603xdef14a_bg002.jpg GRAPHIC 107006
  Complete submission text file 0001558370-25-005254.txt   3293662

Data Files

Seq Description Document Type Size
6 EX-101.SCH vygr-20250603.xsd EX-101.SCH 4697
7 EX-101.DEF vygr-20250603_def.xml EX-101.DEF 4260
8 EX-101.LAB vygr-20250603_lab.xml EX-101.LAB 5834
9 EX-101.PRE vygr-20250603_pre.xml EX-101.PRE 5036
22 EXTRACTED XBRL INSTANCE DOCUMENT vygr-20250603xdef14a_htm.xml XML 267420
Mailing Address 75 HAYDEN AVENUE LEXINGTON MA 02421
Business Address 75 HAYDEN AVENUE LEXINGTON MA 02421 857-259-5340
Voyager Therapeutics, Inc. (Filer) CIK: 0001640266 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37625 | Film No.: 25861334
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)